MedTrace Logo

Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System

NCT01687036 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-12-06

Study results available
· View outcomes & findings →

Summary

Primary Endpoint Safety and tolerability of ablation using the AFreeze Cryoablation System consisting of the ablation CoolLoop® catheter, its steerable sheath and the cryoconsole Cryo-Caddy will be assessed and expressed in number of participants with Adverse Events (AEs).

Conditions

Interventions

DEVICE

Cryoablation

Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System

Sponsors & Collaborators

  • afreeze GmbH

    lead OTHER

Principal Investigators

  • Markus Stuehlinger, MD · Medical University Innsbruck

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-03-31
Completion
2013-06-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01687036 on ClinicalTrials.gov